advertisement
Eye 59
Showing records 1 to 25 | Display all abstracts in Eye69298 Manchester iStent study: 3-year results and cost analysis
Tan SZ
Eye 2016; 30: 1365-1370
69031 Clinical efficacy of modified partial pars plana vitrectomy combined with phacoemulsification for malignant glaucoma
He F
Eye 2016; 30: 1094-1100
69416 Congenital cataract associated with persistent fetal vasculature: findings from IoLunder2
Solebo AL
Eye 2016; 30: 1204-1209
69417 Second intraocular surgery after primary pediatric cataract surgery: indications and outcomes during long-term follow-up at a tertiary eye care center
Sachdeva V
Eye 2016; 30: 1260-1265
69033 Angle closure glaucoma in the Northern Ireland Diabetic Retinopathy Screening Programme
Lagan MA
Eye 2016; 30: 1091-1093
69080 Trabeculectomy with ologen in secondary glaucomas following failed trabeculectomy with MMC: comparative study
El-Saied HM
Eye 2016; 30: 1126-1134
69418 Twenty-four-hour intraocular pressure and ocular perfusion pressure characteristics in newly diagnosed patients with normal tension glaucoma
Quaranta L
Eye 2016; 30: 1481-1489
69078 Glaucoma treatment adherence at a United Kingdom general practice
Tse AP
Eye 2016; 30: 1118-1122
69258 Secondary intraocular lens implantation following infantile cataract surgery: intraoperative indications, postoperative outcomes
Wood KS
Eye 2016; 30: 1182-1186
69132 Revisiting the role of erythropoietin for treatment of ocular disorders
Shirley Ding SL
Eye 2016; 30: 1293-1309
69257 Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial
Fechtner RD
Eye 2016; 30: 1343-1350
68913 Elevated neutrophil-to-lymphocyte ratio in pseudoexfoliation syndrome
Kurtul BE
Eye 2016; 30: 1045-1048
68950 Baseline factors predicting the risk of conversion from ocular hypertension to primary open-angle glaucoma during a 10-year follow-up
Salvetat ML
Eye 2016; 30: 784-795
69258 Secondary intraocular lens implantation following infantile cataract surgery: intraoperative indications, postoperative outcomes
Tadros D
Eye 2016; 30: 1182-1186
69080 Trabeculectomy with ologen in secondary glaucomas following failed trabeculectomy with MMC: comparative study
Abdelhakim MA
Eye 2016; 30: 1126-1134
69031 Clinical efficacy of modified partial pars plana vitrectomy combined with phacoemulsification for malignant glaucoma
Qian Z
Eye 2016; 30: 1094-1100
69418 Twenty-four-hour intraocular pressure and ocular perfusion pressure characteristics in newly diagnosed patients with normal tension glaucoma
Katsanos A
Eye 2016; 30: 1481-1489
69078 Glaucoma treatment adherence at a United Kingdom general practice
Shah M
Eye 2016; 30: 1118-1122
69257 Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial
Myers JS
Eye 2016; 30: 1343-1350
68950 Baseline factors predicting the risk of conversion from ocular hypertension to primary open-angle glaucoma during a 10-year follow-up
Zeppieri M
Eye 2016; 30: 784-795
69298 Manchester iStent study: 3-year results and cost analysis
Au L
Eye 2016; 30: 1365-1370
68913 Elevated neutrophil-to-lymphocyte ratio in pseudoexfoliation syndrome
Ozer PA
Eye 2016; 30: 1045-1048
69417 Second intraocular surgery after primary pediatric cataract surgery: indications and outcomes during long-term follow-up at a tertiary eye care center
Katukuri S
Eye 2016; 30: 1260-1265
69416 Congenital cataract associated with persistent fetal vasculature: findings from IoLunder2
Russell-Eggitt I
Eye 2016; 30: 1204-1209
69132 Revisiting the role of erythropoietin for treatment of ocular disorders
Leow SN
Eye 2016; 30: 1293-1309
